18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: A single-institution retrospective analysis

Lung Cancer

Volumn 67, Issue 1, 2010, Pages 76-80

  Na, Im Il ^a   Byun, Byung Hyun ^a   Kim, Kyeong Min ^a   Cheon, Gi Jeong ^a   Choe, Du Hwan ^a   Koh, Jae Soo ^a   Lee, Duck Yong ^a   Ryoo, Baek Yeol ^a   Baek, HeeJong ^a   Lim, Sang Moo ^a   Yang, Sung Hyun ^a   Kim, Cheol Hyeon ^a   Lee, Jae Cheol ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

EGFR mutation; FDG uptake; Lung cancer; Standardized uptake value

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; GENETIC SCREENING; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; GENETIC TESTING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 71549164313     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.03.010     Document Type: Article

References (34)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2 (2001) 533-543
2. Lee C.-T. Epidemiology of lung cancer in Korea. Cancer Res Treat 34 (2002) 3-7
3. Spiro S.G., and Silvestri G.A. One hundred years of lung cancer. Am J Respir Crit Care Med 172 (2005) 523-529
4. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
5. Gazdar A.F., and Minna J.D. Inhibition of EGFR signaling: all mutations are not created equal. PLoS Med 2 (2005) e377
6. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97 (2005) 339-346
7. Pallis A.G., Voutsina A., Kalikaki A., Souglakos J., Briasoulis E., Murray S., et al. 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer 97 (2007) 1560-1566
8. Greulich H., Chen T.H., Feng W., Janne P.A., Alvarez J.V., Zappaterra M., et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2 (2005) e313
9. Sequist L.V., Bell D.W., Lynch T.J., and Haber D.A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25 (2007) 587-595
10. Sequist L.V., Joshi V.A., Janne P.A., Muzikansky A., Fidias P., Meyerson M., et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 12 (2007) 90-98
11. Dacic S. EGFR assays in lung cancer. Adv Anat Pathol 15 (2008) 241-247
12. Marchetti A., Felicioni L., and Buttitta F. Assessing EGFR mutations. N Engl J Med 354 (2006) 526-528 (Author reply 526-528)
13. Thie J.A. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 45 (2004) 1431-1434
14. Vansteenkiste J.F., Stroobants S.G., Dupont P.J., De Leyn P.R., Verbeken E.K., Deneffe G.J., et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. J Clin Oncol 17 (1999) 3201-3206
15. Sasaki R., Komaki R., Macapinlac H., Erasmus J., Allen P., Forster K., et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23 (2005) 1136-1143
16. Al-Sarraf N., Gately K., Lucey J., Aziz R., Doddakula K., Wilson L., et al. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases. Eur J Cardiothorac Surg 34 (2008) 892-897
17. Goodgame B., Pillot G.A., Yang Z., Shriki J., Meyers B.F., Zoole J., et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol 3 (2008) 130-134
18. Berghmans T., Dusart M., Paesmans M., Hossein-Foucher C., Buvat I., Castaigne C., et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 3 (2008) 6-12
19. Na I.I., Byun B.H., Kang H.J., Cheon G.J., Koh J.S., Kim C.H., et al. 18F-Fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer. Clin Cancer Res 14 (2008) 2036-2041
20. Hoffman E.J., Huang S.C., and Phelps M.E. Quantitation in positron emission computed tomography. 1. Effect of object size. J Comput Assist Tomogr 3 (1979) 299-308
21. Na I.I., Cheon G.J., Choe D.H., Byun B.H., Kang H.J., Koh J.S., et al. Clinical significance of (18)F-FDG uptake by N2 lymph nodes in patients with resected stage IIIA N2 non-small-cell lung cancer: a retrospective study. Lung Cancer 60 (2008) 69-74
22. Na I.I., Kang H.J., Cho S.Y., Koh J.S., Lee J.K., Lee B.C., et al. EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. Eur J Cancer 43 (2007) 520-526
23. Cuzick J. A Wilcoxon-type test for trend. Stat Med 4 (1985) 87-90
24. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23 (2005) 2513-2520
25. Carey K.D., Garton A.J., Romero M.S., Kahler J., Thomson S., Ross S., et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 66 (2006) 8163-8171
26. Mulloy R., Ferrand A., Kim Y., Sordella R., Bell D.W., Haber D.A., et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 67 (2007) 2325-2330
27. Hardin J.A., Wong J.K., Cheeseman C.I., and Gall D.G. Effect of luminal epidermal growth factor on enterocyte glucose and proline transport. Am J Physiol 271 (1996) G509-515
28. Weihua Z., Tsan R., Huang W.C., Wu Q., Chiu C.H., Fidler I.J., et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13 (2008) 385-393
29. Mazumdar M., and Glassman J.R. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med 19 (2000) 113-132
30. Royston P., Altman D.G., and Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 25 (2006) 127-141
31. Schafer H. Constructing a cut-off point for a quantitative diagnostic test. Stat Med 8 (1989) 1381-1391
32. Sugio K., Uramoto H., Ono K., Oyama T., Hanagiri T., Sugaya M., et al. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 94 (2006) 896-903
33. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2 (2005) e17
34. Pham D., Kris M.G., Riely G.J., Sarkaria I.S., McDonough T., Chuai S., et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 24 (2006) 1700-1704